Engflag

Sugammadex

Quick links to important sections

Sugammadex

Sugammadex_SV

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sugammadex

Property Description
Active ingredient Sugammadex
Form Solution for injection
Pharmacological class Selective Relaxant Binding Agent (SRBA)
General use Reversal of muscle paralysis during surgery
Origin Synthetic compound (γ-cyclodextrin derivative)

Sugammadex is a unique prescription-only medication classified as a Selective Relaxant Binding Agent (SRBA), whose primary function is to reverse the action of specific muscle-paralyzing drugs used during general anesthesia for surgery. The active ingredient, Sugammadex, is a synthetic compound derived from a modified γ-cyclodextrin, which provides its distinctive chemical structure. It is administered exclusively by trained healthcare professionals as a sterile solution via intravenous (IV) administration.

Sugammadex: Definition and Pharmacological Class

Sugammadex is a single-ingredient product belonging to a novel pharmacological class: the Selective Relaxant Binding Agents (SRBAs). Its chemical structure, an octasaccharide derivative, is specifically designed to function as an encapsulating agent, immediately distinguishing it from older classes of antagonists used in anesthesia. Sugammadex provides effective and rapid reversal of moderate and deep rocuronium-induced neuromuscular blockade; the drug is a tool used to help patients regain control of their muscles and vital functions following general anesthesia.

Composition, Form, and General Purpose in Surgery

Supplied as an aqueous solution for injection, the medication’s core general purpose is the rapid reversal of neuromuscular blockade induced by specific aminosteroid neuromuscular blocking agents, namely rocuronium and vecuronium, at the conclusion of surgery. By acting as a highly selective molecular "cage," Sugammadex captures the free rocuronium or vecuronium molecules in the bloodstream, thereby neutralizing their effect and facilitating the quick restoration of the patient's spontaneous muscle function. This direct action confirms its precise mode of mechanism.

What side effects are possible with Sugammadex?

Possible Side Effects and Safety Information

The safety profile of Sugammadex, as documented in official regulatory sources, classifies potential adverse reactions based on their physiological effects and frequency of occurrence.

Adverse Reaction Classifications

Side effects are categorized across multiple body systems (System-Organ Classes). Common adverse reactions typically include gastrointestinal effects such as nausea and vomiting, as well as nervous system effects like headache and dysgeusia (taste disturbance).

Classification Examples of Officially Documented Effects
Common Nausea, vomiting, headache, dysgeusia, pain (including injection site)
Rare Anaphylaxis, marked bradycardia, cardiac arrest, hypersensitivity reactions

Serious Safety Considerations

Official labeling specifically documents serious, though rare, systemic events. These include anaphylaxis and anaphylactic shock (severe immune system disorders) and marked bradycardia (severe slowing of the heart rate) or cardiac arrest, which have been observed to occur rapidly following administration. There is also a low-incidence risk of the recurrence of neuromuscular blockade.

Constraints for Specific Populations

Regulatory documents outline specific constraints for patient groups. Use is not recommended in individuals with severe renal impairment (creatinine clearance < 30 mL/min) due to delayed excretion. Use is also not recommended for infants under two years of age due to limited clinical experience. For patients receiving hormonal contraceptives, Sugammadex can temporarily reduce the effectiveness of the contraceptive, presenting a theoretical risk of failure.

Overdose and Emergency Response

Sugammadex Overdose and When to Seek Help

Official regulatory documentation states that high doses of Sugammadex (up to 96 mg/kg) administered in clinical trials did not produce a unique, distinct toxic syndrome or new adverse effects beyond those already recognized. Overdosage is considered unlikely because the medication is administered exclusively by trained anesthesia professionals.

Manifestations and Urgent Actions

The official concern focuses on critical systemic reactions that may occur upon administration, regardless of dose:

  • Urgent Medical Attention Required: Immediate medical attention must be sought for any signs of a severe allergic reaction (anaphylaxis) or significant, sudden drops in heart rate (marked bradycardia), which have been documented to occur shortly after administration.
  • No Specific Antidote: There is no specific antidote known for Sugammadex overdose.
  • Management: Treatment is mandated to be symptomatic and supportive. This includes ensuring adequate ventilation and maintaining a patent airway. Continuous hemodynamic monitoring is required, and the use of anticholinergic agents is specified if marked bradycardia is observed. Sugammadex and its complex can be removed by hemodialysis.
  • Special Consideration: The medication is primarily eliminated by the kidneys. Its use is not recommended in patients with severe renal impairment as prolonged exposure may occur due to significantly delayed clearance of the drug and its complex.

Therapeutic Uses of Sugammadex

Sugammadex is relevant in clinical settings that involve acute or unstable symptom patterns, specifically those related to drug-induced muscle paralysis following general anesthesia. The medication is commonly used to address the condition of neuromuscular blockade, which involves symptoms of increased neurological or muscular activity after procedures where specific muscle relaxants, rocuronium and vecuronium, were administered. The application of Sugammadex is relevant in contexts involving heightened systemic burden, specifically helping to manage the temporary symptoms of increased neurological or muscular activity in adults and pediatric patients.

Reversal of Postoperative Residual Weakness

This primary use is applied in addressing symptom clusters related to residual muscle weakness and other symptoms that interfere with daily functioning after an operation. Sugammadex contributes to improved comfort during periods of heightened symptoms, which may assist with maintaining functional stability and supports addressing the symptoms of increased neurological or muscular activity.

“Sugammadex is commonly used when short-term symptomatic assistance is needed to resolve the effects of specific muscle relaxants after surgical procedures.”

The medication is commonly used across conditions presenting with acute episodes, relevant for managing both moderate and deep neuromuscular blockade. This application is commonly used to help with managing those symptoms that create noticeable physiological strain, such as those related to impaired respiratory function.

Quick Fact: Relief for Incomplete Neuromuscular Recovery

Management of Deep Paralysis States

The medication is considered relevant for managing symptoms associated with deep and profound neuromuscular blockade. This use is commonly used to help with addressing conditions characterized by periods of heightened symptoms. This application supports patients during difficult episodes of heightened symptoms, which may assist with achieving a desirable recovery of physiological stability when the procedure is complete.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sugammadex?

The population eligibility for Sugammadex is strictly defined by regulatory documents, establishing who is permitted to receive the medicine and who is formally restricted. The drug is contraindicated in patients with a known hypersensitivity to sugammadex or any of its components. This is an absolute prohibition stated in the official prescribing information.

Restrictions and Special Populations

Population Group Regulatory Status
Severe Renal Impairment (CrCl < 30 mL/min) Not recommended for use, as the drug is primarily cleared by the kidneys.
Pediatric Patients Approved for use in adults (18+) and in pediatric patients (from birth up to 17 years old).
Pregnancy / Lactation No sufficient data; use requires a medical evaluation of potential benefit versus risk.
Severe Hepatic Impairment Caution should be exercised, particularly if combined with coagulopathy.

Sugammadex is generally permitted for use in adults and approved pediatric age groups. However, its use is not established for reversal of neuromuscular blockade in the Intensive Care Unit (ICU) setting, limiting its scope to controlled surgical environments.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents highlight that Sugammadex, due to its steroid-binding structure, is involved in two primary types of drug interactions: Capturing Interactions and Displacement Interactions.

Pharmacodynamic and Exposure Interactions

Interacting Agents / Classes Official Interaction Type Regulatory Restriction or Requirement
Hormonal Contraceptives Capturing Interaction (Reduced Exposure) Patients must use an additional non-hormonal contraceptive method for 7 days following administration.
Toremifene Displacement Interaction (Recurrence Risk) Concomitant use can delay the reversal of neuromuscular blockade, increasing the risk of recurrence.
Therapeutic Anticoagulants Pharmacodynamic Effect on Coagulation Caution should be exercised in patients receiving therapeutic anticoagulation due to transient prolongation of aPTT and PT(INR).

Interaction Details and Constraints

The binding of Sugammadex to the steroid structure of Progestogens (a component of hormonal contraceptives) leads to a clinically relevant decrease in their plasma concentration. This exposure modification is officially considered equivalent to missing a dose of an oral contraceptive. For oral hormonal contraceptives, patients are required to follow the specific missed-dose advice in the product leaflet.

No specific interactions with food, alcohol, or herbal products are formally documented or established in the regulatory prescribing information.

Population-Specific Notes

The need for caution regarding bleeding risk is heightened in patients who are receiving therapeutic anticoagulation or in those with severe hepatic impairment when it is accompanied by coagulopathy, due to Sugammadex's documented transient effects on blood coagulation parameters.

Mechanism of Action

How Sugammadex Works

Sugammadex acts as a Selective Relaxant Binding Agent (SRBA), functioning via direct chemical sequestration rather than receptor interaction. The mechanism begins when the modified gamma-cyclodextrin molecule directly targets and binds circulating molecules of the aminosteroid neuromuscular blocking agents (rocuronium or vecuronium).

This binding forms a stable, water-soluble, 1:1 host-guest inclusion complex, rendering the relaxant pharmacologically inactive . This chemical sequestration rapidly lowers the concentration of free relaxant in the plasma, creating a steep concentration gradient shift between the plasma and the neuromuscular junction (NMJ).

This gradient actively pulls the muscle relaxant molecules off the nicotinic acetylcholine receptors (nAChRs) at the motor end-plate. The resultant molecular displacement immediately frees the receptors for binding, enabling the transmission of the nerve signal. The consequence of receptor recovery is the re-establishment of signaling competence in the somatic motor pathway, leading to the re-establishment of muscle fiber depolarization.

Dosage and Administration Information

How to Use Sugammadex — Administration Guidelines

Sugammadex is supplied as a solution for injection (100 mg/mL) and must be administered exclusively via a single, rapid intravenous (IV) bolus injection over a 10-second period. The correct dose is calculated based on the patient's actual body weight and is determined by the specific level of residual muscle paralysis, which must be assessed using neuromuscular monitoring.

Administration Scope

Dosing Schedule (Weight-Based):

  • For routine reversal of moderate blockade, the standard dose is 2 mg/kg.
  • For deep blockade, the recommended dose is 4 mg/kg.
  • For immediate reversal of rocuronium soon after administration, a high dose of 16 mg/kg is recommended.

Preparation and Procedural Specifics:

To increase accuracy, the 100 mg/mL solution may be diluted to 10 mg/mL using 0.9% sodium chloride, particularly for pediatric patients. The medication is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/min). Administration must always occur under the supervision of a trained anaesthetist or specialist familiar with neuromuscular blocking agents.

Age-Group Rules:

The standard 2 mg/kg and 4 mg/kg regimens are recommended for pediatric patients aged 2 to 17 years for rocuronium reversal. The 16 mg/kg dose for immediate reversal is not studied or recommended in this younger age group.

Resulting Procedural Structure

The use of Sugammadex follows a strict protocol that requires the administrator to:

  • Determine the necessary dose based on actual body weight and the monitored level of neuromuscular blockade.
  • Administer the specified dose as a single bolus injection into an existing IV line.
  • Observe the required minimum waiting period before re-administering any aminosteroid neuromuscular blocking agent, which varies based on the Sugammadex dose given.

The established instructions establish a highly specific, time-critical protocol for use, mandating administration via a rapid intravenous bolus only. This protocol is structured around three distinct, weight-based dosage tiers, each tied to a measurable physiological state (the depth of paralysis). These established protocols govern the exact method, quantity, and procedural context for the drug's proper administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Sugammadex

Evidence for Use in Moderate Muscle Paralysis Reversal

Sugammadex was studied for the reversal of muscle paralysis (neuromuscular blockade) that is commonly induced by certain medications, specifically rocuronium or vecuronium, during general anesthesia. The core evidence for this use comes from large, controlled research studies known as Randomized Controlled Trials (RCTs). These trials were used in research exploring how symptoms change over time as patients recovered. Researchers examined outcomes related to systemic or functional imbalance, focusing on the measurement of muscle function recovery after the surgical procedure.

The findings from these trials, which have been aggregated in Systematic Reviews and Meta-analyses, describe patterns observed in the studies related to the timing of muscle function recovery. Studies monitored the time it took for patients to achieve a key objective measure of recovery, known as the Train-of-Four ratio, to a specific physiological threshold. These studies contribute to the broader evidence landscape.

Evidence for Use in Deep and Profound Muscle Paralysis

Sugammadex was also evaluated in separate research trials specifically focusing on its profile during states of deep or profound muscle paralysis. This application is relevant in research contexts involving fluctuating or unstable symptoms related to severe neuromuscular blockade. These studies also included specialized Pharmacokinetic (PK) and Pharmacodynamic (PD) studies to understand the drug's action under these demanding conditions.

The primary outcomes monitored in this research focused on the Time to Neuromuscular Recovery (TTNMR), but also included outcomes describing episodic or acute changes such as the time needed to restore spontaneous breathing. Research highlights changes measured during the study period, with findings indicating a specific physiological response even when the paralyzing agent's effects are most intense.

Research on Long-Term Outcomes and Follow-Up

The core research for Sugammadex, including the clinical trials that supported its initial availability, primarily focused on short-term symptom changes that occur within the operating room and the immediate hours thereafter. The follow-up durations were limited, concentrating on monitoring physiological strain or stress during the acute recovery period. Because the focus of the research was on immediate recovery, long-term effects are not fully established regarding any lasting impact on muscle function or daily functioning or activity level.

Evidence in Special Patient Populations

Research was evaluated in specific patient groups to understand if the observations from the general adult population apply consistently across all people. This includes studies where the agent was observed in pediatric patients (children), ranging from infants to older children. Studies research examined recovery patterns in these different age groups, recognizing that children may exhibit different physiological responses than adults.

Evidence in Patients with Impaired Kidney Function

Dedicated research was studied for patients with moderate or severe renal impairment. Because the drug is eliminated primarily through the kidneys, these studies research examined the physiological disposition of the agent in the body. While research provides insight into short-term changes, data for certain groups remain insufficient regarding potential accumulation in the most severely compromised patients.

What Remains Uncertain About the Research Landscape

While the existing research contributes to the broader evidence landscape, there are areas where more data are still needed. For instance, sample sizes were modest in some of the initial trials, which means that results apply only to the populations studied and may not perfectly predict outcomes across the entire patient spectrum. Furthermore, as Sugammadex was studied for conditions characterized by fluctuating or episodic manifestations, research provides context but not individual predictions: research does not determine whether an individual will respond similarly to the patterns observed in the group studies. Research is ongoing to provide further clarity in these areas.

Key Studies & References Safety of Sugammadex in Pregnancy, Pediatrics, and Renal Failure - Anesthesia Patient Safety Foundation (APSF)

Frequently Asked Questions (FAQ)

Common questions about Sugammadex (FAQ)

Q: Is Sugammadex used for pain relief after surgery?

Official documents define the use of Sugammadex as the reversal of muscle paralysis caused by specific medicines (rocuronium or vecuronium) during the end of a surgical procedure. Its regulatory indication is solely to restore muscle function and breathing, and not for pain management.

Q: Does Sugammadex cause a change in heart rate?

Official prescribing information documents list changes in heart rate among the possible adverse reactions. These documented changes can include bradycardia (a slower-than-normal heart rate) and hypotension (low blood pressure) or tachycardia (a faster-than-normal heart rate) and hypertension (high blood pressure).

Q: Why is Sugammadex called a 'reversal agent'?

It is officially designated as a reversal agent because its primary function is to reverse the muscle-paralyzing effects of certain drugs used during general anesthesia. Its action is designed to stop the effect of the muscle relaxant, helping to restore muscle function.

Q: Can Sugammadex be used in emergency situations?

Yes, official dosing guidelines include a specific high-dose regimen for the immediate reversal of rocuronium-induced muscle paralysis. This particular application is used when there is an urgent clinical need to quickly stop the effects of the muscle relaxant.

Q: Is it true that Sugammadex can affect birth control pills?

Official drug information states that Sugammadex may temporarily reduce the effectiveness of hormonal contraceptives (like birth control pills). Official information suggests this reduction in effect is similar to missing a dose of an oral contraceptive, and an additional non-hormonal contraceptive method is necessary for seven days following administration.

Q: Does Sugammadex interact with blood thinners like warfarin?

Regulatory documents advise that caution is necessary in people taking therapeutic anticoagulants (blood thinners). This is because Sugammadex has documented transient (temporary) effects on blood coagulation parameters.

Q: What happens to Sugammadex once it's done its job in the body?

After Sugammadex binds to the muscle relaxant, the two molecules form a stable, inactive complex. This complex is then eliminated from the body primarily through the kidneys. Official information notes that the drug is mostly eliminated unchanged.

Q: Is it possible to receive too much Sugammadex?

Regulatory documents have described overdosage in studies of healthy volunteers who received doses much higher than recommended. In these specific instances, no significant adverse reactions or safety concerns were reported.

Q: Does Sugammadex stay in the body for a long time?

In healthy adults, the drug is eliminated relatively quickly, with an elimination half-life of approximately 2 hours. The elimination process is significantly slower in people with severe kidney impairment, according to official prescribing information.

Q: Can Sugammadex be used to reverse all types of muscle relaxants?

No. Sugammadex is a selective binding agent, and regulatory documents specify that it is only indicated for the reversal of neuromuscular blockade induced by the aminosteroid muscle relaxants rocuronium or vecuronium.

Q: Can someone be allergic to Sugammadex itself?

Yes. Official documents state the drug is contraindicated (should not be used) in patients with a known hypersensitivity or allergy to Sugammadex or any of its components. Serious allergic reactions, including anaphylaxis, have been officially documented as rare adverse effects.

Q: Is there any risk of the muscle relaxant 'coming back' after Sugammadex is given?

Official labeling documents a low-incidence risk of the recurrence of neuromuscular blockade, meaning the muscle relaxant effect could temporarily return. This event may be associated with using an insufficient dose or the displacement of the captured muscle relaxant by another drug.

Q: Does Sugammadex contain any common allergens like penicillin or latex?

The excipients (inactive ingredients) of the drug, as listed in the official prescribing information, generally do not include common allergens such as penicillin or latex. The primary components are the active ingredient and standard inactive ingredients used to formulate the solution.

Q: Is Sugammadex used for anything other than reversing muscle paralysis from surgery?

The drug’s official regulatory indication is exclusively the reversal of neuromuscular blockade (muscle paralysis) induced by rocuronium or vecuronium in patients undergoing surgery.

Q: Do you feel pain when Sugammadex is injected?

Pain at the injection site is listed in regulatory documents as a common adverse reaction.

Q: Is Sugammadex linked to any specific long-term health issues?

The clinical trials supporting the drug's approval focused on the acute recovery period following surgery. Official documents note that long-term effects are not fully established because the patient follow-up periods in these initial studies were limited.

Q: Does Sugammadex affect other medications a person takes daily?

Official information indicates that Sugammadex may cause certain drugs to temporarily become less effective. This risk is primarily noted for hormonal contraceptives but is possible for other medications that share a similar steroid chemical structure.

Q: How does the doctor know when to administer Sugammadex?

The decision to administer the drug and the dose to be used are determined based on the specific level of residual muscle paralysis. This level must be objectively measured by the healthcare professional using a medical device dedicated to neuromuscular monitoring.

Q: Are there any dietary restrictions or pre-operative steps related to Sugammadex?

Regulatory documents explicitly state that no specific interactions with food, alcohol, or herbal products are formally documented. There are no specific restrictions related to diet or specific steps required for the drug itself before the procedure listed in the official label.

Q: Why do some doctors choose Sugammadex instead of older medications?

Studies have indicated that Sugammadex provides a faster and more predictable reversal of muscle paralysis compared to traditional methods. This profile characteristic is often referenced in regulatory summaries.

Q: Does Sugammadex have an impact on blood pressure?

Official prescribing information lists changes in blood pressure as documented adverse reactions. These include both hypotension (low blood pressure) and hypertension (high blood pressure).

Q: Are there any known interactions with herbal supplements?

Regulatory documents state that no specific interactions with herbal products are formally documented or established in the official prescribing information.

Q: Can Sugammadex be used in people with liver disease?

Official guidance advises that caution should be exercised in patients with severe hepatic impairment (severe liver disease). Caution is advised, particularly when the liver disease is accompanied by a blood clotting disorder.

Q: Is it possible for Sugammadex to not work for some people?

Clinical trials have noted that a small number of patients experienced a delayed or minimal response to the drug. This possibility is addressed in the official safety information.

Q: What research is available regarding Sugammadex and recovery time from surgery?

Regulatory summaries of the research indicate that the drug significantly reduces the time to recovery of muscle function. Studies measured the time it took for patients to reach a key physiological recovery threshold faster than with older methods.

Q: Does the body break down Sugammadex, or is it eliminated unchanged?

Regulatory documents state that the drug is eliminated from the body mostly unchanged as the stable complex it forms with the muscle relaxant. This means that no significant metabolism (chemical breakdown) of the drug takes place inside the body.

How should Sugammadex be stored and disposed of?

How to Store and Dispose of Sugammadex?

Sugammadex injection must be stored according to regulatory requirements to ensure its stability.

Storage Conditions

Entity Requirement
Temperature Store at 25°C (77°F); permitted excursions are 15°C to 30°C (59°F to 86°F).
Protection Must be protected from light and stored in the outer carton.
Prohibition Do not freeze the product.
Child Safety Keep out of the sight and reach of children.

Handling and Disposal

The injection is a single-dose solution without preservatives; therefore, any unused portion must be discarded. If the solution is diluted for use, it is stable for up to 48 hours under refrigeration or at room temperature. The medication and its waste must not be thrown away via wastewater or household waste; disposal must follow professional pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sugammadex found in:

A-Z Index: